Frontlight ResearchEarly access
Taking people in United StatesPhase 3
Growth Hormone Replacement Therapy in Veterans With Mild Traumatic Brain Injury (mTBI) and Adult Growth Hormone Deficiency (AGHD)
Key facts
- Who runs it
- VA Office of Research and Development
- Where
- Ann Arbor, Aurora, Birmingham, Dallas, Decatur, Houston, Kansas City, Minneapolis, Oklahoma City, Omaha, Phoenix, Salisbury, San Antonio, San Diego, Seattle, and Washington D.C., United StatesSee the 16 sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 172 people, planned
- Started
- 13 Jan 2025
- Expected to end
- 30 Sept 2029
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Somatropin
- Placebo
- Record updated
- 13 October 2026
Who can take part
- Age
- 21 years to 55 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 21 criteriaShow less
Who can take part
- OEF/OIF/OND Veteran
- Score of 18 or more on Combat Experiences sub-scale of Deployment Risk and Resilience Inventory-2 (DRRI-2)
- One or more mild traumatic brain injury (mTBI) sustained during military service at least 12 months prior to the screening date, as noted via the CRAFT survey
- Growth hormone (GH) deficiency diagnosed by: macimorelin stimulation test (cut point 5.1 micrograms per liter), or glucagon stimulation test (cut point: 3 micrograms per liter (mcg/L) for body mass index up to 25; cut point 1 micrograms per liter for body mass index (BMI) 25 and above) and IGF-I lab values have to be less than or equal to +1 SDS at baseline
- Score of 11 or more on QoL-AGHDA
- 4-week stability on any psychotropic medications
- 3-month stability on all other hormone treatments
- Able and willing to provide informed consent to participate in this study, and complete study protocol
Who cannot take part
- History of bipolar disorder, schizophrenia, or other concurrent psychotic disorder
- Contraindication to recombinant human growth hormone (rhGH) therapy
- Currently enrolled in any other interventional study unless prior approval is provided by the study chairs and the study sponsor (Cooperative Studies Program)
- History of moderate or severe traumatic brain injury (TBI)
- History of neurologic disorder other than traumatic brain injury with substantial impact on quality of life
- Acute medical illness, active infection, cancer or decompensated chronic medical illness
- Evidence of substance use disorder, -other than mild alcohol or cannabis use disorder-, or urine toxicology evidence of the use of an illicit drug (excluding cannabis), in the past 6 months. Nicotine use is allowed
- Active suicidal ideation (no plan required) as determined by a score of 2 points or more on the Columbia Suicide Severity Rating Scale (C-SSRS) suicidal ideation rating, or overt suicidal behavior in the past 6 months
- Score less than or equal to 41 on Trial 2 or Retention Trial of the Test of Memory and Malingering (TOMM)
- body mass index (BMI) > 40 or body weight > 350 pounds
- Pituitary anatomy documented by an MRI using a sella protocol within the last 2 years indicating abnormalities consistent with an etiology other than mild-TBI (i.e.; pituitary mass)
- Women who are pregnant or of child-bearing potential not on contraception
- Current use of the following: growth hormone, estrogen or estrogen-like dietary supplements, progestin, IGF-I, or chronic glucocorticoid use in supraphysiologic doses
The main criteria, as questions
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 21 and 55 years old?
Where in United States
- VA Ann Arbor Healthcare System, Ann Arbor, MIAnn Arbor, United StatesContact: Richard J Auchus, MDTaking people
- Rocky Mountain Regional VA Medical Center, Aurora, COAurora, United StatesContact: Lisa Brenner, PhDTaking people
- Birmingham VA Medical Center, Birmingham, ALBirmingham, United StatesContact: Ripu Jindal, MDNot yet recruiting
- VA North Texas Health Care System Dallas VA Medical Center, Dallas, TXDallas, United StatesContact: Kyaw Soe, MDNot yet recruiting
- Atlanta VA Medical and Rehab Center, Decatur, GADecatur, United StatesContact: Deane V Walker, MHA BS ABNo longer taking part
- Michael E. DeBakey VA Medical Center, Houston, TXHouston, United StatesContact: Sanjay Mediwala, MDTaking people
- Kansas City VA Medical Center, Kansas City, MOKansas City, United StatesContact: Mariana Garcia-Touza, MDNot yet recruiting
- Minneapolis VA Health Care System, Minneapolis, MNMinneapolis, United StatesContact: Shalamar Sibley, MDTaking people
- Oklahoma City VA Medical Center, Oklahoma City, OKOklahoma City, United StatesContact: Calin Prodan, MDNot yet recruiting
- Omaha VA Nebraska-Western Iowa Health Care System, Omaha, NEOmaha, United StatesContact: Cyrus V DeSouza, MBBSNot yet recruiting
- Phoenix VA Health Care System, Phoenix, AZPhoenix, United StatesContact: Sherman Harman, MDNot yet recruiting
- Salisbury W.G. (Bill) Hefner VA Medical Center, Salisbury, NCSalisbury, United StatesContact: Robin hurley, MDNot yet recruiting
- South Texas Health Care System, San Antonio, TXSan Antonio, United StatesContact: Devjit Tripathy, MDNot yet recruiting
- VA San Diego Healthcare System, San Diego, CASan Diego, United StatesContact: Richard L Hauger, MDNot yet recruiting
- VA Puget Sound Health Care System Seattle Division, Seattle, WASeattle, United StatesContact: Megan M Herodes, BSTaking people
- Washington DC VA Medical Center, Washington, DCWashington D.C., United StatesContact: Sen Sabyasachi, MDNot yet recruiting
About the trial
What the trial wants to find out
The purpose of this study is to determine whether growth hormone replacement therapy (GHRT) is effective versus placebo in the improvement of Quality of Life in patients with adult growth hormone deficiency (AGHD) and mild traumatic brain injury (mTBI).
The 2 groups in the trial
- Growth Hormone Replacement TherapyExisting treatment, for comparison
Recombinant Human Growth Hormone
Treatment: Somatropin
- PlaceboPlacebo, for comparison
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- CSP #2018 - Growth Hormone Replacement Therapy in Veterans With Mild Traumatic Brain Injury (mTBI) and Adult Growth Hormone Deficiency (AGHD)
- Criteria questions
- Built from NCT04867317, who can take part
- Record updated
- 13 October 2026